Showing results (741-750 of 4,871) with videos related to

Sort By:
Pageof 488
Urologic Oncology|January 24, 2009
Snail expression is an independent predictor of tumor recurrence in superficial bladder cancersFranck Bruyere, Benjamin Namdarian, Niall M Corcoran, et al.
Urologic Oncology|January 24, 2009
Enhanced GSTP1 expression in transitional cell carcinoma of urinary bladder is associated with altered apoptotic pathwaysMarija Pljesa-Ercegovac, Ana Savic-Radojevic, Dejan Dragicevic, et al.
Urologic Oncology|January 28, 2009
Renal cell carcinoma with inferior vena cava thrombus: the Hacettepe experienceSertac Yazici, Kubilay Inci, Cenk Yucel Bilen, et al.
Urologic Oncology|January 28, 2009
Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinomaNitika Badjatia, Abhigyan Satyam, Prabhjot Singh, et al.
Urologic Oncology|December 27, 2008
Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumorsDimitrios Pectasides, Eirini Pectasides, George Papaxoinis, et al.
Urologic Oncology|December 30, 2008
Oncogenic activation of androgen receptorHsing-Jien Kung, Christopher P Evans
Urologic Oncology|December 30, 2008
Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?Eric A Klein, Jay Ciezki, Patrick A Kupelian, et al.
Urologic Oncology|December 30, 2008
Optimal timing of chemotherapy in androgen independent prostate cancerIan D Schnadig, Tomasz M Beer
Urologic Oncology|October 14, 2008
Impact of radical prostatectomy positive surgical margins on fear of cancer recurrence: results from CaPSUREY Mark Hong, Jim C Hu, Alan T Paciorek, et al.
Urologic Oncology|October 14, 2008
Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel aloneOrazio Caffo, Teodoro Sava, Evi Comploj, et al.
Pageof 488